Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Delcath Systems Q3 2025 Earnings Call - Chopin Trial Validates Combination Therapy Driving Growth and Expansion
Delcath Systems reported strong Q3 2025 results, backed by new clinical data from the Chopin trial that shows superior efficacy of combination liver-directed and systemic therapy in metastatic uveal m...
- Chopin trial showed statistically significant improvement in one-year progression-free survival (54.7% vs 15.8%) and median overall survival (23.1 vs 19.6 months) for combination regimen over perfusion alone.
- Combination therapy involving HEPZATO with systemic immunotherapy may alter clinical practice and overcome physician reluctance to use liver-directed therapy in patients with extrahepatic disease.
- Q3 2025 revenue from HEPZATO sales was $19.3 million, almost doubling from $10 million in Q3 2024, with gross margins around 87%.
- +12 more takeaways
Shoals Technologies Group 3Q 2025 Earnings Call - Record Revenue and Expanding Battery Energy Storage Solutions Drive Growth
Shoals Technologies Group reported a strong third quarter 2025 with record revenue of $135.8 million, marking a 32.9% year-over-year increase and a robust backlog and awarded orders (BLAO) record of $...
- Shoals Technologies delivered record Q3 revenue of $135.8 million, up 32.9% YoY and 22.5% sequentially.
- Backlog and awarded orders hit a company record at $720.9 million, a 21% increase YoY, with $575 million scheduled for shipment by Q3 2026.
- Book-to-bill ratio was strong at 1.4, underlining solid demand heading into 2026.
- +17 more takeaways
Waters Corporation Q3 2025 Earnings Call - Strong Instrument Replacement Cycle and BD Combination Set Stage for Growth
Waters Corporation reported a robust third quarter in 2025, showcasing 8% sales growth and 16% adjusted EPS growth, surpassing guidance amid a sustained instrument replacement cycle and strategic prod...
- Q3 2025 sales rose 8% (constant currency) to $800 million, with instruments up 6% led by LCMS systems.
- Adjusted EPS grew 16% to $3.40, beating guidance by 20 cents.
- Instrument replacement cycle is in early to mid-innings, tracking low single-digit CAGR versus 2019, with steady customer upgrade demand.
- +9 more takeaways
Gladstone Commercial Corporation Q3 2025 Earnings Call - Industrial Focus Fuels Portfolio Growth Amid Cap Rate Compression
Gladstone Commercial Corporation reported a steady quarter in Q3 2025 marked by strategic portfolio growth and balance sheet strengthening. The company increased its industrial asset concentration to ...
- Gladstone raised its industrial portfolio concentration to 69% of annualized rents, up from 63% at the start of 2025.
- Acquired a $54.5 million six-facility industrial manufacturing portfolio during Q3, contributing to $206 million in acquisitions year-to-date.
- Portfolio occupancy reached 99.1%, the highest since Q1 2019, with a weighted average lease term of 7.5 years, longest since Q1 2020.
- +9 more takeaways
Brightstar Lottery Q3 2025 Earnings Call - Pure-Play Lottery Focus Drives Strong Growth and Innovation
Brightstar reported better-than-expected Q3 2025 results, marking its transformation into a pure-play lottery company focused on steady organic growth and technological innovation. Revenue rose 7% yea...
- Brightstar completed its transition to a pure-play lottery business after the $4 billion sale of its gaming division.
- Q3 2025 revenue grew 7% to $629 million, driven by 8% same-store sales growth globally.
- US multi-state jackpot revenue surged, powered by a $1.8 billion Powerball jackpot.
- +17 more takeaways
Verastem Oncology 3Q 2025 Earnings Call - Strong Commercial Launch of Avnaptifexinjacopac Drives Revenue Growth
Verastem Oncology delivered a solid third quarter characterized by $11.2 million in net product revenue from its newly approved therapy Avnaptifexinjacopac for KRAS mutated recurrent low grade serous ...
- Verastem reported $11.2 million net product revenue in 3Q 2025 from Avnaptifexinjacopac, surpassing expectations in its first full launch quarter.
- Commercial adoption is strong among both academic centers and community oncologists with 133 prescribers to date.
- The launch strategy focuses on physician engagement, patient initiation and retention, and streamlined reimbursement, all trending positively.
- +9 more takeaways
EVE Holding Inc Q3 2025 Earnings Call - Full-Scale Prototype Ready for Flight Testing & Strategic Expansion to Middle East
EVE Holding reported a strong Q3 2025 with steady progress on its eVTOL program. The company is completing tests on its engineering prototype and expects its first test flight by late 2025 or early 20...
- EVE is finishing final tests on its engineering prototype with first flight expected by end of 2025 or early 2026.
- A new supplier contract with Embraer secures landing gear manufacturing, enhancing aircraft ground maneuverability and energy efficiency.
- The Iron Bird cockpit simulator, replicating actual vehicle systems, has logged 10,000+ test hours supporting integration, certification, and aftermarket readiness.
- +9 more takeaways
Cabot Corporation Q4 FY2025 Earnings Call - Navigating Volume Declines Amid Turbulent Trade and Macro Environment
In fiscal year 2025, Cabot Corporation delivered a record adjusted EPS of $7.25 despite declining volumes across segments and a challenging macroeconomic and geopolitical landscape. The company levera...
- Cabot posted a record adjusted EPS of $7.25 in fiscal 2025, up 3% year-over-year despite volume declines.
- Volumes were down in both Reinforcement Materials and Performance Chemicals segments, with Reinforcement Materials EBIT down 5% and Performance Chemicals EBIT up 18%.
- Strong operational execution, global asset optimization, and cost reductions offset volume weakness and supported earnings growth.
- +7 more takeaways
Sequans Communications Q3 2025 Earnings Call - Proactive Bitcoin Debt Reduction and Accelerating IoT Revenue Growth
Sequans Communications reported a decisive shift in its capital structure with a strategic sale of Bitcoin holdings to reduce convertible debt by 50%, aiming to optimize its debt-to-net asset value ra...
- Sequans reduced convertible debt by 50% via tactical Bitcoin sale to improve debt-to-net asset value ratio to approximately 35%.
- The company remains committed to its Bitcoin treasury strategy and aims to opportunistically accumulate Bitcoin through various financing avenues including ADS buyback and ATM program.
- Sequans’ net equivalent cash position, considering Bitcoin NAV minus debt, stands above $170 million or roughly $12 per ADS, while the share price trades at a steep discount around $7.
- +7 more takeaways
First Watch Restaurant Group Q3 2025 Earnings Call - Strong Growth Driven by New Restaurant Performance and Marketing Strategy
First Watch Restaurant Group delivered a robust third quarter in 2025 with total revenue up 25.6%, propelled by strong new restaurant openings, positive same-restaurant sales growth of 7.1%, and strat...
- Q3 2025 total revenue rose 25.6%, driven by new restaurant openings, same-store sales growth of 7.1%, and franchise acquisitions.
- Same-restaurant traffic growth reached its best level in over two years at 2.6%, with positive momentum in onsite dining and delivery channels.
- Restaurant-level operating profit margin improved by 80 basis points year-over-year to 19.7%, despite 3% commodity inflation and 3.6% labor inflation.
- +13 more takeaways